Search Result

Results for "

Antithrombotic Agent

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) Bacterial (1) Bcl-2 Family (1) Biochemical Assay Reagents (3) Calcium Channel (1) Caspase (1) Cytochrome P450 (3) Drug Isomer (1) Endogenous Metabolite (2) Factor Xa (3) Factor XI (1) Fungal (1) Glycoprotein VI (3) IKZF Family (1) Influenza Virus (1) Integrin (2) Interleukin Related (1) Ligands for E3 Ligase (1) Molecular Glues (1) P2Y Receptor (5) PARP (1) Potassium Channel (1) Prostaglandin Receptor (6) Reference Standards (5) Thrombin (9) Thrombopoietin Receptor (1)
By Research Areas:	Cancer (6) Cardiovascular Disease (35) Endocrinology (1) Infection (3) Inflammation/Immunology (5) Metabolic Disease (2)

By Targets:

Apoptosis (3)

Bacterial (1)

Bcl-2 Family (1)

Biochemical Assay Reagents (3)

Calcium Channel (1)

Caspase (1)

Cytochrome P450 (3)

Drug Isomer (1)

Endogenous Metabolite (2)

Factor Xa (3)

Factor XI (1)

Fungal (1)

Glycoprotein VI (3)

IKZF Family (1)

Influenza Virus (1)

Integrin (2)

Interleukin Related (1)

Ligands for E3 Ligase (1)

Molecular Glues (1)

P2Y Receptor (5)

PARP (1)

Potassium Channel (1)

Prostaglandin Receptor (6)

Reference Standards (5)

Thrombin (9)

Thrombopoietin Receptor (1)

By Research Areas:

Cancer (6)

Cardiovascular Disease (35)

Endocrinology (1)

Infection (3)

Inflammation/Immunology (5)

Metabolic Disease (2)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Nombre del producto	Target	Áreas de investigación	Chemical Structure

HY-112624P

Dextran T500 (MW 500,000) 1 Publications Verification Dextran 500; Dextran D500; Dextran T500(MW 440000-560000)	Biochemical Assay Reagents	Others
Dextran T500 MW 500,000 (Dextran 500; Dextran D500; Dextran T500 MW 440000-560000) is a polymer of anhydroglucose with the average molecular weight of 500,000. Dextran T500 MW 500,000 exhibits good biodegradability and good biocompatibility, that is utilized in food, pharmaceutics, cosmetics, and research area .

HY-17459

Clopidogrel hydrogen sulfate Maximum Cited Publications 30 Publications Verification (S)-(+)-Clopidogrel bisulfate; (S)-(+)-Clopidogrel hydrogen sulfate	Cytochrome P450 P2Y Receptor	Cardiovascular Disease Cancer
Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC₅₀s of 18.2 nM and 524 nM, respectively . Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation ．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .

HY-10274

Dabigatran etexilate 4 Publications Verification BIBR 1048	Thrombin	Cardiovascular Disease
Dabigatran etexilate (BIBR 1048) is an orally active proagent of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation .

HY-P2970

Stem bromelain	Apoptosis PARP Caspase Bcl-2 Family Bacterial Interleukin Related	Infection Inflammation/Immunology Cancer
Stem bromelain (EC 3.4.22.32) is a cysteine protease and antibacterial agent. Stem bromelain can be isolated from the stem of the pineapple (Ananas comosus). Stem bromelain induces dose-dependent secretion of IL-12p70, and IL-6, induces Apoptosis, causes cleavage of full-length PARP protein, Caspase 3, and Caspase 9, increases Bax, and decreases Bcl-2. Stem bromelain possesses various fibrinolytic, antiedema, antithrombotic, and anti-inflammatory activities. Stem bromelain also exhibits in vivo antitumor and antileukemic activities, as well as antimetastatic effects. Stem bromelain has antimycobacterial activity. Stem bromelain provides protection against lead poisoning .

HY-B1271

Sulfinpyrazone 4 Publications Verification G-28315	Endogenous Metabolite	Inflammation/Immunology
Sulfinpyrazone (G-28315) is an orally active and potent uricosuric agent for chronic and intermittent gouty arthritis. Sulfinpyrazone has antithrombotic and platelet inhibitory effects .

HY-129611

Bromelain	Apoptosis	Inflammation/Immunology Cancer
Bromelain is an anti-inflammatory agent derived from pineapple stem that acts through down-regulation of plasma kininogen, inhibition of Prostaglandin E2 expression, degradation of advanced glycation end product receptors and regulation of angiogenic biomarkers as well as antioxidant action upstream in the COX-pathway . Bromelain exhibits various fibrinolytic, antiedematous, antithrombotic, and anti-inflammatory activities. Bromelain also possesses some anticancerous activities and promotes apoptotic cell death .

HY-112624D

Dextran T60 (MW 60,000) Dextran 60; Dextran D60; Dextran T60(MW 54000-66000)	Biochemical Assay Reagents	Others
Dextran T60 MW 60,000 (Dextran 60; Dextran D60; Dextran T60 MW 54000-66000) is a polymer of anhydroglucose with the average molecular weight of 60,000. Dextran T60 MW 60,000 exhibits good biodegradability and good biocompatibility, that is utilized in food, pharmaceutics, cosmetics, and research area .

HY-122542B

PPACK TFA 2 Publications Verification	Ligands for E3 Ligase Molecular Glues IKZF Family	Cardiovascular Disease
PPACK TFA is an orally active, selective molecular glue degrader targeting IKZF2. Through a molecular glue mechanism, PPACK TFA binds to CRBN, recruits IKZF2 to form a ternary complex, and promotes its ubiquitination and proteasomal degradation. This further converts inhibitory regulatory T cells (T_reg) into effector-like T cells, enhances CD8 ⁺ T cell responses, and modulates the T_eff:T_reg balance. PPACK TFA also increases the production of the inflammatory cytokine IL-2 and reduces the suppressive activity of T_reg. PPACK TFA can be used in cancer immunotherapy research, and exhibits a synergistic effect when combined with immune checkpoint inhibitors such as anti-PD1 .

HY-101054

NQ301 1 Publications Verification	Thrombin	Cardiovascular Disease
NQ301 is an antithrombotic agent; inhibits collagen-challenged rabbit platelet aggregation with an IC₅₀ of 10 mg/mL.

HY-112624Q

Dextran T800 (MW 800,000) Dextran 800; Dextran D800; Dextran T800(MW 750000-850000)	Biochemical Assay Reagents	Others
Dextran T800 MW 800,000 (Dextran 800; Dextran D800; Dextran T800 MW 750000-850000) is a polymer of anhydroglucose with the average molecular weight of 800,000. Dextran T800 MW 800,000 exhibits good biodegradability and good biocompatibility, that is utilized in food, pharmaceutics, cosmetics, and research area .

HY-16991

Terutroban 1 Publications Verification S-18886	Prostaglandin Receptor	Cardiovascular Disease Metabolic Disease
Terutroban (S-18886) is a selective and orally active thromboxane-prostaglandin (TP) receptor antagonist with an IC₅₀ of 16.4 nM. Terutroban inhibits TXA2 and prostaglandin endoperoxide receptors. Terutroban is a potent antithrombotic agent and possesses anti-atherosclerotic and anti-vasoconstrictor properties .

HY-10274A

Dabigatran etexilate mesylate 4 Publications Verification BIBR 1048MS; Dabigatran etexilate methanesulfonate	Thrombin	Cardiovascular Disease
Dabigatran etexilate mesylate (BIBR 1048MS) is an orally active proagent of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate mesylate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation .

HY-N1745A

3-Deoxysappanchalcone 2 Publications Verification	Influenza Virus	Infection Inflammation/Immunology Cancer
3-Deoxysappanchalcone is a kinase inhibitor and antiviral agent. 3-Deoxysappanchalcone directly targets MET, EGFR, AKT, mTOR, p38 MAPK, JNK, thrombin, FXa, and influenza virus neuraminidase, thereby regulating related signaling pathways. 3-Deoxysappanchalcone induces cell cycle arrest, ROS production, and apoptosis. 3-Deoxysappanchalcone exhibits anti-inflammatory, anti-allergic, anticoagulant, and antithrombotic activities. 3-Deoxysappanchalcone is applicable to research related to gefitinib-resistant lung cancer, esophageal squamous cell carcinoma, thrombosis, and influenza virus infection .

HY-117290

BMS-962212	Factor Xa	Cardiovascular Disease
BMS-962212 is a factor XIa (FXIa) inhibitor with a K_i of 0.7 nM against human FXIa and a K_i of 3 nM against rabbit FXIa. BMS-962212 blocks thrombosis while preserving normal hemostatic function. BMS-962212 is applicable to thrombosis-related research .

HY-106784

Ajoene	Fungal Apoptosis	Infection Cancer
Ajoene, a garlic-derived compound, is an *antithrombotic* and antifungal agent. Ajoene inhibits proliferation and induces apoptosis of human leukaemia CD34-negative cells including HL-60, U937, HEL and OCIM-I. Anticancer activities .

HY-10264S

Edoxaban-d6 DU-176-d₆	Factor Xa Thrombin	Cardiovascular Disease
Edoxaban-d₆ is deuterium labeled Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention. Edoxaban is also a weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10000-fold selectivity for FXa. Edoxaban has antithrombotic properties and has potential for thromboembolic diseases treatment .

HY-B1271R

Sulfinpyrazone (Standard) G-28315 (Standard)	Reference Standards Endogenous Metabolite	Inflammation/Immunology
Sulfinpyrazone (Standard) is the analytical standard of Sulfinpyrazone. This product is intended for research and analytical applications. Sulfinpyrazone (G-28315) is an orally active and potent uricosuric agent for chronic and intermittent gouty arthritis. Sulfinpyrazone has antithrombotic and platelet inhibitory effects .

HY-U00383

Rafigrelide 3,3-Dimethylanagrelide	Thrombopoietin Receptor	Cardiovascular Disease
Rafigrelide is a platelet-lowering agent, and also has antithrombotic properties.

HY-129496

NP-313	Thrombin	Cardiovascular Disease
NP-313 is a potent antithrombotic agent that inhibits platelet aggregation and activation. NP-313 has dual inhibition of thromboxane A 2 synthesis and selective inhibition of SOCC-mediated Ca ²⁺ inward flow .

HY-16991A

Terutroban sodium 1 Publications Verification S-18886 sodium	Prostaglandin Receptor	Cardiovascular Disease Metabolic Disease
Terutroban (S-18886) sodium is a selective and orally active thromboxane-prostaglandin (TP) receptor antagonist with an IC₅₀ of 16.4 nM. Terutroban sodium inhibits TXA2 and prostaglandin endoperoxide receptors. Terutroban sodium is a potent antithrombotic agent and possesses anti-atherosclerotic and anti-vasoconstrictor properties .

HY-10274R

Dabigatran etexilate (Standard) BIBR 1048 (Standard)	Reference Standards Thrombin	Cardiovascular Disease
Dabigatran etexilate (Standard) is the analytical standard of Dabigatran etexilate. This product is intended for research and analytical applications. Dabigatran etexilate (BIBR 1048) is an orally active proagent of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation .

HY-105559A

Viquidil hydrochloride Quinotoxine hydrochloride	Drug Isomer	Cardiovascular Disease
Viquidil hydrochloride (Quinotoxine hydrochloride), an isomer of Quinidine, is a cerebral vasodilator agent. Viquidil hydrochloride shows antithrombotic activity .

HY-105559

Viquidil Quinotoxine	Potassium Channel	Cardiovascular Disease
Viquidil (Quinotoxine), an isomer of Quinidine, is a cerebral vasodilator agent. Viquidil shows antithrombotic activity .

HY-117824

L-703014	Integrin	Others
L-703014 is a fibrinogen receptor antagonist, with the IC₅₀ of 94 nM, that acts as a novel parenteral and potential oral antithrombotic agent .

HY-106932

L-734217	Integrin	Cardiovascular Disease
L-734217 is an orally active and potent fibrinogen receptor antagonist and an antithrombotic agent. L-734217 is excreted largely by the renal route and partly into the bile in dogs. L-734217 is promising for research of thrombotic disorders .

HY-19052

Trombodipine PCA-4230	Calcium Channel	Cardiovascular Disease
Trombodipine is an antithrombotic agent, inhibiting platelet aggregation .

HY-105919

Naroparcil	Factor Xa	Cardiovascular Disease
Naroparcil is an orally active antithrombotic agent. Naroparcil exhibits antithrombotic effects in rabbit Wessler stasis model with EC₅₀s of 21.9 mg/kg and 36.0 mg/kg after respectively intravenous injection and oral administration .

HY-P5889

Thrombin receptor peptide ligand	Thrombin	Cardiovascular Disease
Thrombin receptor peptide ligand is a thrombin receptor antagonist peptide that can be used as an antithrombotic agent .

HY-125615

DMP 728 methanesulfonate	Glycoprotein VI	Cardiovascular Disease Others
DMP 728 methanesulfonate is a platelet glycoprotein (GP) IIb/IIIa receptor antagonist. DMP 728 methanesulfonate shows dose-dependent antiplatelet and antithrombotic effects. DMP 728 methanesulfonate can be used in the study of effective antithrombotic agents in thromboembolic diseases of coronary and peripheral arteries .

HY-110043

(±)-Clopidogrel hydrochloride	P2Y Receptor	Cardiovascular Disease
(±)-Clopidogrel hydrochloride is an antithrombotic agent that is ADP-selective and orally available. (±)-Clopidogrel hydrochloride inhibits platelet aggregation by inhibiting the binding of ADP to its platelet receptors .

HY-119410

Linotroban HN11500	Prostaglandin Receptor	Cardiovascular Disease
Linotroban (HN11500), a Sulotroban (HY-158332) derivative, is an orally active, potent non-prostanoid thromboxane receptor antagonist (TXRA) with a strong antiplatelet profile. Linotroban is used as antithrombotic agent .

HY-163645

P2Y12 antagonist 1	P2Y Receptor	Cardiovascular Disease
P2Y12 antagonist 1 (compound 26) is a P2Y12 receptor antagonist with a Ki of 3.13 μM. P2Y12 antagonist 1 can be used to inhibit platelet aggregation and is a potential antithrombotic agent .

HY-115911

GPVI antagonist 2	Glycoprotein VI	Cardiovascular Disease
GPVI antagonist 2 (Compound 1) is a potential antagonist of Glycoprotein VI (GPVI). IC₅₀ values of GPVI antagonist 2 are, respectively, 0.35 μM for collagen, 0.80 μM for CRP, 195.2 μM for convulxin and 81.38 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 2 is a promising antiplatelet agent .

HY-137227

15(R)-PTA2 15(R)-Pinanethromboxane A2	Prostaglandin Receptor	Cardiovascular Disease
15(R)-PTA2 (15(R)-Pinanethromboxane A2) is an antithrombotic agent that inhibits platelet aggregation. 15(R)-PTA2 inhibits stable prostaglandin endoperoxide analog-induced constriction of feline coronary arteries and stabilizes hepatic lysosomes. 15(R)-PTA2 also inhibits thromboxane synthase but has no effect on prostacyclin synthase .

HY-115912

GPVI antagonist 3	Glycoprotein VI	Cardiovascular Disease
GPVI antagonist 3 (Compound 2) is a potential antagonist of Glycoprotein VI (GPVI). IC₅₀ values of GPVI antagonist 3 are, respectively, 1.01 μM for collagen, 1.92 μM for CRP, 7.24 μM for convulxin and 51.74 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 3 is a promising antiplatelet agent .

HY-10274AR

Dabigatran etexilate mesylate (Standard) BIBR 1048MS (Standard); Dabigatran etexilate methanesulfonate (Standard)	Reference Standards Thrombin	Cardiovascular Disease
Dabigatran etexilate (mesylate) (Standard) is the analytical standard of Dabigatran etexilate (mesylate). This product is intended for research and analytical applications. Dabigatran etexilate mesylate (BIBR 1048MS) is an orally active proagent of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate mesylate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation .

HY-17459R

Clopidogrel hydrogen sulfate (Standard) (S)-(+)-Clopidogrel bisulfate (Standard); (S)-(+)-Clopidogrel hydrogen sulfate (Standard)	Reference Standards Cytochrome P450 P2Y Receptor	Cardiovascular Disease Cancer
Clopidogrel (hydrogen sulfate) (Standard) is the analytical standard of Clopidogrel (hydrogen sulfate). This product is intended for research and analytical applications. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC₅₀s of 18.2 nM and 524 nM, respectively . Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation ．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .

HY-17459S

Clopidogrel-d3 hydrogen sulfate (S)-(+)-Clopidogrel bisulfate-d3; (S)-(+)-Clopidogrel-d3 hydrogen sulfate	P2Y Receptor Cytochrome P450	Cardiovascular Disease
Clopidogrel-d₃ (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate . Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC₅₀s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .

HY-P4721

Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) sulfated	Thrombin	Cardiovascular Disease
Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is a hirugen-like peptide, and has high affnity for thrombin than Hirugen, with a K_D < 100 nM. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is an antithrombotic agent. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) inhibits the thrombin-induced fibrin clot formation with an IC50 value of 0.087 μM .

HY-105363

RGH-1962	Others	Cardiovascular Disease
RGH-1962 is an orally active antithrombotic agent. RGH-1962 prevents endotoxin-induced decreases in fibrinogen level and platelet count, reduces the level of fibrin degradation products and inhibits the endotoxin-induced enhancement of fibrinolytic activity in a rabbit model of endotoxin-induced disseminated intravascular coagulation. RGH-1962 can be used for the study of thrombotic diseases .

HY-105364

RGH-1875 hydriodide GYKI 39521 hydriodide	Others	Cardiovascular Disease
RGH-1875 (GYKI 39521) hydriodide is the hydriodide of RGH-1875. RGH-1875 is an orally active antithrombotic agent. RGH-1875 prevents endotoxin-induced decreases in fibrinogen level and platelet count, reduces the level of fibrin degradation products and inhibits the endotoxin-induced enhancement of fibrinolytic activity in a rabbit model of endotoxin-induced disseminated intravascular coagulation. RGH-1875 can be used for the study of thrombotic diseases .

HY-106115

Vintoperol RGH 2981; RT-3003	Others	Cardiovascular Disease
Vintoperol (RGH 2981; RT-3003) is a potent and orally active antithrombotic agent. Vintoperol interferes with platelet aggregation and has antithrombotic effects, protecting mice from retrograde and anterograde amnesia induced by traumatic brain injury .

HY-W169940

NP-184	Prostaglandin Receptor	Cardiovascular Disease
NP-184 is a novel orally active antithrombotic agent. NP-184 selectively inhibits TXA2 synthase activity with an IC₅₀ value of 4.3 μM. NP-184 has antiplatelet and antithrombotic activities. NP-184 can be used in the research of thromboembolic diseases .

HY-117290A

BMS-962212 hydrochloride	Factor XI	Cardiovascular Disease
BMS-962212 hydrochloride is a selective coagulation factor XIa inhibitor and acute antithrombotic agent. BMS-962212 hydrochloride can be used in the research of thrombosis .

HY-16991R

Terutroban (Standard) S-18886 (Standard)	Prostaglandin Receptor Reference Standards	Cardiovascular Disease Endocrinology
Terutroban (Standard) is the analytical standard of Terutroban. This product is intended for research and analytical applications. Terutroban (S-18886) is a selective and orally active thromboxane-prostaglandin (TP) receptor antagonist with an IC500 of 16.4 nM. Terutroban inhibits TXA2 and prostaglandin endoperoxide receptors. Terutroban is a potent antithrombotic agent and possesses antiatherosclerotic and antivasoconstrictor properties .

Cat. No.	Nombre del producto	Type

HY-112624P

Dextran T500 (MW 500,000) 1 Publications Verification Dextran 500; Dextran D500; Dextran T500(MW 440000-560000)	Biochemical Assay Reagents
Dextran T500 MW 500,000 (Dextran 500; Dextran D500; Dextran T500 MW 440000-560000) is a polymer of anhydroglucose with the average molecular weight of 500,000. Dextran T500 MW 500,000 exhibits good biodegradability and good biocompatibility, that is utilized in food, pharmaceutics, cosmetics, and research area .

HY-112624D

Dextran T60 (MW 60,000) Dextran 60; Dextran D60; Dextran T60(MW 54000-66000)	Biochemical Assay Reagents
Dextran T60 MW 60,000 (Dextran 60; Dextran D60; Dextran T60 MW 54000-66000) is a polymer of anhydroglucose with the average molecular weight of 60,000. Dextran T60 MW 60,000 exhibits good biodegradability and good biocompatibility, that is utilized in food, pharmaceutics, cosmetics, and research area .

HY-112624Q

Dextran T800 (MW 800,000) Dextran 800; Dextran D800; Dextran T800(MW 750000-850000)	Biochemical Assay Reagents
Dextran T800 MW 800,000 (Dextran 800; Dextran D800; Dextran T800 MW 750000-850000) is a polymer of anhydroglucose with the average molecular weight of 800,000. Dextran T800 MW 800,000 exhibits good biodegradability and good biocompatibility, that is utilized in food, pharmaceutics, cosmetics, and research area .

Cat. No.	Nombre del producto	Target	Research Area

HY-122542B

PPACK TFA 2 Publications Verification	Ligands for E3 Ligase Molecular Glues IKZF Family	Cardiovascular Disease
PPACK TFA is an orally active, selective molecular glue degrader targeting IKZF2. Through a molecular glue mechanism, PPACK TFA binds to CRBN, recruits IKZF2 to form a ternary complex, and promotes its ubiquitination and proteasomal degradation. This further converts inhibitory regulatory T cells (T_reg) into effector-like T cells, enhances CD8 ⁺ T cell responses, and modulates the T_eff:T_reg balance. PPACK TFA also increases the production of the inflammatory cytokine IL-2 and reduces the suppressive activity of T_reg. PPACK TFA can be used in cancer immunotherapy research, and exhibits a synergistic effect when combined with immune checkpoint inhibitors such as anti-PD1 .

HY-P5889

Thrombin receptor peptide ligand	Thrombin	Cardiovascular Disease
Thrombin receptor peptide ligand is a thrombin receptor antagonist peptide that can be used as an antithrombotic agent .

HY-P4721

Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) sulfated	Thrombin	Cardiovascular Disease
Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is a hirugen-like peptide, and has high affnity for thrombin than Hirugen, with a K_D < 100 nM. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is an antithrombotic agent. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) inhibits the thrombin-induced fibrin clot formation with an IC50 value of 0.087 μM .

Cat. No.	Nombre del producto	Category	Target	Chemical Structure

HY-P2970

Stem bromelain	Ananas comosus(L.) Merr. Structural Classification Productos naturales Classification of Application Fields Bromeliaceae Plants Inflammation/Immunology Disease Research Fields Cancer	Apoptosis PARP Caspase Bcl-2 Family Bacterial Interleukin Related
Stem bromelain (EC 3.4.22.32) is a cysteine protease and antibacterial agent. Stem bromelain can be isolated from the stem of the pineapple (Ananas comosus). Stem bromelain induces dose-dependent secretion of IL-12p70, and IL-6, induces Apoptosis, causes cleavage of full-length PARP protein, Caspase 3, and Caspase 9, increases Bax, and decreases Bcl-2. Stem bromelain possesses various fibrinolytic, antiedema, antithrombotic, and anti-inflammatory activities. Stem bromelain also exhibits in vivo antitumor and antileukemic activities, as well as antimetastatic effects. Stem bromelain has antimycobacterial activity. Stem bromelain provides protection against lead poisoning .

HY-B1271

Sulfinpyrazone 4 Publications Verification G-28315	Productos naturales Classification of Application Fields Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Endogenous Metabolite
Sulfinpyrazone (G-28315) is an orally active and potent uricosuric agent for chronic and intermittent gouty arthritis. Sulfinpyrazone has antithrombotic and platelet inhibitory effects .

HY-N1745A

3-Deoxysappanchalcone 2 Publications Verification	Structural Classification Chalcones Flavonoids Classification of Application Fields Leguminosae Caesalpinia sappan L. Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields Source Classification	Influenza Virus
3-Deoxysappanchalcone is a kinase inhibitor and antiviral agent. 3-Deoxysappanchalcone directly targets MET, EGFR, AKT, mTOR, p38 MAPK, JNK, thrombin, FXa, and influenza virus neuraminidase, thereby regulating related signaling pathways. 3-Deoxysappanchalcone induces cell cycle arrest, ROS production, and apoptosis. 3-Deoxysappanchalcone exhibits anti-inflammatory, anti-allergic, anticoagulant, and antithrombotic activities. 3-Deoxysappanchalcone is applicable to research related to gefitinib-resistant lung cancer, esophageal squamous cell carcinoma, thrombosis, and influenza virus infection .

HY-106784

Ajoene	Infection Productos naturales Liliaceae Classification of Application Fields Plants Disease Research Fields A．Sativam L. var．Viviparum Regel Source Classification	Fungal Apoptosis
Ajoene, a garlic-derived compound, is an *antithrombotic* and antifungal agent. Ajoene inhibits proliferation and induces apoptosis of human leukaemia CD34-negative cells including HL-60, U937, HEL and OCIM-I. Anticancer activities .

HY-B1271R

Sulfinpyrazone (Standard) G-28315 (Standard)	Structural Classification Productos naturales Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Sulfinpyrazone (Standard) is the analytical standard of Sulfinpyrazone. This product is intended for research and analytical applications. Sulfinpyrazone (G-28315) is an orally active and potent uricosuric agent for chronic and intermittent gouty arthritis. Sulfinpyrazone has antithrombotic and platelet inhibitory effects .

Cat. No.	Nombre del producto	Chemical Structure

HY-10264S

Edoxaban-d6

Edoxaban-d₆ is deuterium labeled Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention. Edoxaban is also a weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10000-fold selectivity for FXa. Edoxaban has antithrombotic properties and has potential for thromboembolic diseases treatment .

HY-17459S

Clopidogrel-d3 hydrogen sulfate

Clopidogrel-d₃ (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate . Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC₅₀s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .

Consulta en línea

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Saludo			Country or Region *
Nombre del solicitante *			Nombre de la Organizaciòn *
Department *
Direcciòn del E-mail *			Nombre del producto *
Cat. No.			Requested quantity *
Número de teléfono *
Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent:

Antithrombotic Agent

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products